← Back to home

RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS

Clinical trials for RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS explained in plain language.

Never miss a new study

Get alerted when new RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS trials appear

Sign up with your email to follow new studies for RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Head-to-Head kidney cancer drug trial seeks better control

Disease control Ongoing

This study compares two existing drugs, cabozantinib and sunitinib, to see which is safer and more effective at controlling advanced kidney cancer that has spread. It is for patients with specific, less common types of kidney cancer. Participants are randomly assigned to take one…

Matched conditions: RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS

Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Mar 30, 2026 14:30 UTC

RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS

Get alerted when new RENAL CELL CARCINOMA ASSOCIATED WITH XP11.2 TRANSLOCATIONS/TFE3 GENE FUSIONS trials appear

Head-to-Head kidney cancer drug trial seeks better control